Effect of Clinical Pharmacist-Led Pharmaceutical Care in Major Depressive Disorder
Key facts
- Who runs it
- Marmara University
- Where
- Türkiye1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 186 people enrolled
- Started
- 25 Dec 2024
- Ended
- 30 Jun 2026
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Clinical Pharmacist-Led Pharmaceutical Care
- Record updated
- 16 November 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Adults aged 18-65 years
- Diagnosis of major depressive disorder (MDD) by a psychiatrist according to DSM-5 criteria
- Receiving maintenance antidepressant treatment for at least one month
- Ability to communicate effectively in Turkish
- Willingness to participate in the study and provision of written informed consent
- Availability to complete the scheduled follow-up assessments
Who cannot take part
- Drug or substance dependence
- History of bipolar disorder, psychotic disorders, or other severe psychiatric disorders that could interfere with study participation
- Active cancer
- Pregnancy
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This randomized controlled trial evaluated the effects of a six-month clinical pharmacist-led pharmaceutical care intervention on medication adherence, beliefs about medicines, and health-related quality of life in adults diagnosed with major depressive disorder (MDD) receiving antidepressant treatment.
Read full original descriptionShow less
A total of 186 participants were randomized in a 1:1 ratio to receive either structured pharmaceutical care in addition to usual psychiatric care or usual psychiatric care alone. Of these, 170 participants completed the six-month follow-up.
The intervention included individualized patient counseling, medication review, identification and management of medication-related problems, and telephone follow-up every two weeks.
Medication adherence was assessed using the Medication Adherence Report Scale (MARS-5), beliefs about medicines using the Turkish Beliefs about Medicines Questionnaire (BMQ-T), and health-related quality of life using the EQ-5D-3L and EQ-VAS. Assessments were conducted at baseline, Month 3, and Month 6.
The 2 groups in the trial
- Clinical Pharmacist-Led Pharmaceutical CareTreatment being tested
Participants assigned to this group received structured clinical pharmacist-led pharmaceutical care in addition to usual psychiatric care for six months. The intervention included individualized patient education and counseling, medication review, identification and management of medication-related problems, monitoring of adverse effects, and telephone follow-up every two weeks.
- Usual Psychiatric CareNo study treatment, for comparison
Participants assigned to the control group received usual psychiatric care, including routine clinical follow-up and antidepressant treatment as prescribed by their treating psychiatrist. No additional structured clinical pharmacist-led pharmaceutical care intervention was provided during the six-month study period. Outcome assessments were conducted at baseline, Month 3, and Month 6.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effect of Clinical Pharmacist-Led Pharmaceutical Care on Medication Adherence, Beliefs About Medicines, and Health-Related Quality of Life in Patients With Major Depressive Disorder: A Randomized Controlled Trial
- Record updated
- 16 November 2026